[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504403":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":36,"locations":45,"responsibleParty":82,"collaborators":85,"id":88,"slug":10,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":10,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":95,"minAge":96,"maxAge":10,"enrollmentInfo":97,"targetDuration":10,"studyType":100,"phases":10,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"pNETs",null,"Patients with pancreatic neuroendocrine tumors (pNETs). The prospective cases enrolled by the sub-center shall strictly comply with the study's inclusion\u002Fexclusion criteria, consistent with the main center, and no independent adjustment of the enrollment criteria is allowed.",[13],"Diagnostic Test: Blood collection",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy","Healthy volunteers. The prospective cases enrolled by the sub-center shall strictly comply with the study's inclusion\u002Fexclusion criteria, consistent with the main center, and no independent adjustment of the enrollment criteria is allowed.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"PDAC","Patients with pancreatic ductal adenocarcinoma (PDAC) . The prospective cases enrolled by the sub-center shall strictly comply with the study's inclusion\u002Fexclusion criteria, consistent with the main center, and no independent adjustment of the enrollment criteria is allowed.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"SPT","Patients with solid pseudopapillary tumor (SPT) of pancreas. The prospective cases enrolled by the sub-center shall strictly comply with the study's inclusion\u002Fexclusion criteria, consistent with the main center, and no independent adjustment of the enrollment criteria is allowed.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"DIAGNOSTIC_TEST","Blood collection","Blood collection for fragmentomic profiles of plasma cell-free DNA. The sub-center shall use the same blood collection consumables (EDTA anticoagulant vacutainer tubes) and blood collection volume (10ml) as the main center; plasma separation shall be completed within 2 hours after blood collection, and all operations shall comply with the study's unified SOP.",[15,19,23,9],[33],{"name":34,"affiliation":5,"role":35},"Xianjun Yu, MD, PhD","PRINCIPAL_INVESTIGATOR",[37,41],{"name":34,"role":38,"phone":39,"phoneExt":10,"email":40},"CONTACT","021-64175590-88503","yuxianjun@fudanpci.org",{"name":42,"role":38,"phone":43,"phoneExt":10,"email":44},"Shunrong Ji, MD, PhD","13788993956","jishunrong@fudanpci.org",[46,67],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Fudan University shanghai cancer center","RECRUITING","Shanghai","Shanghai Municipality","200032","China",{"type":54,"coordinates":55},"Point",[56,57],121.45806,31.22222,{"lat":57,"lon":56},[60,62,64],{"name":61,"role":38,"phone":43,"phoneExt":10,"email":10},"Shunrong Ji, MD,PhD",{"name":63,"role":35,"phone":10,"phoneExt":10,"email":10},"Xianjun Yu",{"name":65,"role":66,"phone":10,"phoneExt":10,"email":10},"Shunrong Ji","SUB_INVESTIGATOR",{"facility":68,"status":48,"city":69,"state":70,"zip":71,"country":52,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"West China Hospital, Sichuan University","Chengdu","Sichuan","610041",{"type":54,"coordinates":73},[74,75],104.06667,30.66667,{"lat":75,"lon":74},[78],{"name":79,"role":38,"phone":80,"phoneExt":10,"email":81},"Doctor","086-18019216797","zwh0105@126.com",{"type":35,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Xian-Jun Yu","President of Shanghai Pancreatic Cancer Institute",[86],{"name":87,"class":6},"West China Hospital","100504403",false,"NCT05847855","Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors","A Prospective Study of Plasma Cell-free DNA Fragmentomics for Early Detection of Pancreatic Neuroendocrine Tumors and Differential Diagnosis of Solid Pancreatic Tumors","Inclusion Criteria:\n\n* Age 18 and above, regardless of gender;\n* Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* No obvious surgical contraindications;\n* Able to comply with research plans, follow-up plans, and other protocol requirements;\n* Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n* Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Currently diagnosed with other types of tumors or any cancer history;\n* Diagnosed with familial syndromes;\n* Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;\n* Recipient of blood transfusion within 30 days prior to study blood draw;\n* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;\n* Poor health condition and not suitable for blood draw;\n* Any other disease\u002Fcondition deemed not suitable for study enrollment by researcher.",true,"ALL","18 Years",{"count":98,"type":99},1000,"ESTIMATED","OBSERVATIONAL","This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.",[103,104],"Pancreatic Neuroendocrine Tumor","Solid Pancreatic Neoplasms",[106,107,108,109,110],"Pancreatic neuroendocrine tumor","cell-free DNA","fragmentomics","early detection","Solid pancreatic neoplasms","2026-03-23",{"date":113,"type":114},"2026-03-25","ACTUAL",{"date":116,"type":114},"2023-02-27",{"date":118,"type":99},"2026-06-30",{"name":5,"class":6},2]